Smith & Nephew plc
In the published model solve dated 2026-Q2, anchored at $30.12, Smith & Nephew plc (SNN) is priced for +6.4% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 11, 2026 from SEC EDGAR filings.
• Smith+Nephew closed its 12-Point Plan with the numbers it promised: 2025 revenue of $6.16 billion, trading margin up 160 basis points to 19.7 percent, free cash flow up 52.5 percent, and a portfolio spanning implants, robotics, sports medicine and wound care that its 20-F frames as ⟦"driving procedural innovation"⟧ (accession 0001104659-26-028258) [Source: FY2025 results, March 2026]. • The risk is a turnaround premium priced as durable compounding: at about 34 times record-basis operating inc
Is SNN overvalued? See what's priced in →
275 institutional managers reported holding SNN in 13F filings for the quarter ended 2026-03-31. Together they hold about 4% of the company; the top 10 hold 2%. 41 opened new positions that quarter. Held by Goldman Sachs, Morgan Stanley, Dimensional Fund Advisors, among others. On the short side, 3.2M shares were sold short as of the 2026-06-15 count, about 0.4% of shares outstanding (2.7 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
SNN has cut its share count 1.1% over the past five years. It pays a dividend, and has paid one every year in our records (11 and counting). Cash returned over the past three years: $984.00M in dividends.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 11, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.